GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Nateglinide - STARLIX oral tablets

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

GlobalRPh RX List - STARLIX oral tablets

Product / population
Adults with type 2 diabetes; selected STARLIX renal sections.
Renal method
Source qualitative renal groups; PK cohorts use CrCl and indexed eGFR
Source revision
STARLIX portion 10/2021; generic portion 4/2015
Retrieved
2026-09-10
Local review status
Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Before use: Nateglinide - STARLIX oral tablets

No-adjustment wording coexists with ESRD metabolite accumulation; it is not a safety clearance.

What to reconcile: Confirm the exact product, indication, renal measure and full source before prescribing.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Rxlist

GlobalRPh RX List - STARLIX oral tablets

Open original reference

GlobalRPh-hosted RX List · Adults with type 2 diabetes; selected STARLIX renal sections.

Renal method: Source qualitative renal groups; PK cohorts use CrCl and indexed eGFR
Source date: STARLIX portion 10/2021; generic portion 4/2015
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Confirm the exact product, indication, renal measure and full source before prescribing.

Dialysis evidence: Removal information only - not a dialysis regimen

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

The same source reports M1 metabolite accumulation in ESRD that may increase glucose-lowering effects. Hemodialysis-related metabolite removal does not establish a supplemental dose.

Skip the meal-associated dose if a meal is skipped. Monitor for hypoglycemia, especially with renal impairment.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

STARLIX - renal statement
Source renal groupSource-specific dose / instruction
Mild to severe renal impairmentNo dose adjustment recommended in the selected mirror
Read the retained text before reformatting

STARLIX - renal statement

Source renal groupSource-specific dose / instruction
Mild to severe renal impairmentNo dose adjustment recommended in the selected mirror

The same source reports M1 metabolite accumulation in ESRD that may increase glucose-lowering effects. Hemodialysis-related metabolite removal does not establish a supplemental dose.

Skip the meal-associated dose if a meal is skipped. Monitor for hypoglycemia, especially with renal impairment.

RDM63-rxlist-nateglinide-1466ab6797-C1 · Source locator: Renal impairment; PK Specific Populations; dosage meal instructions

Source-specific limits

The same source reports M1 metabolite accumulation in ESRD that may increase glucose-lowering effects. Hemodialysis-related metabolite removal does not establish a supplemental dose.

Skip the meal-associated dose if a meal is skipped. Monitor for hypoglycemia, especially with renal impairment.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/starlix-drug/
Retrieved
2026-09-10
Renal-function method
Source qualitative renal groups; PK cohorts use CrCl and indexed eGFR
Source date/version
STARLIX portion 10/2021; generic portion 4/2015
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
e385b22779adc40f42761d82efc5fd6991421f87728c4b76f02b4a0b9f011a34

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=nateglinide&s1=RDM63-rxlist-nateglinide-1466ab6797&h1=9741d0475e30234b8498e4aacee177fc134413365bfb43425ab24b2a70afd5f6